A Phase 2 interventional study of Placebo and Romiplostim in MDS, Myelodysplastic Syndromes and Thrombocytopenia, sponsored by Amgen. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-11-07.
Sponsored by Amgen · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Myelodysplastic Syndromes by Amgen — none open to participants now, none under way, none of them phase 3. Myelodysplastic Syndromes · Amgen.
Among the 11 studies in Myelodysplastic Syndromes by Amgen, this one has the largest enrollment, is the only one that started in 2008, is one of 5 in phase 2, and was the 6th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 324 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 11 studies in Myelodysplastic Syndromes by Amgen is open now. The open studies under Myelodysplastic Syndromes, anywhere →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2008.
This study's enrollment of 250 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 72 across the 11 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Myelodysplastic Syndromes by Amgen, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The Data Monitoring Committee (DMC) for study 20060198 recommended that all subjects discontinue treatment of study drug and continue to be followed for long term follow-up. Amgen adopted the DMC recommendation.
This is a Phase 2, multicenter, randomized, double blind, placebo controlled study designed to assess the efficacy and safety of romiplostim (formerly, AMG 531) treatment in thrombocytopenic MDS patients. The study is composed of a 26-week placebo controlled test treatment period (romiplostim versus Placebo), a 4 week interim wash-out period, a 24-week placebo controlled extended treatment period, and a 4-week follow-up period followed by an End of Study (EOS) visit. During the interim wash-out period, a bone marrow biopsy will be performed in the absence of growth factor to assess changes in the marrow. In the extended treatment period, safety assessments will continue and participants will be allowed to receive any standard of care treatments for MDS. Patients will be followed for survival for an additional 60 months following the End of Study (EOS) visit.
Inclusion Criteria: • Diagnosis of MDS using the World Health Organization (WHO) classification for myeloid neoplasms as assessed during the screening period. • Per MDS International Prognostic Scoring System (IPSS), low or intermediate-1 risk MDS as assessed during the screening period. • Mean of the 2 counts taken within 4 weeks prior to randomization must be: - ≤ 20 x 10\^9/L, (with no individual count >30 x 10\^9/L during the screening period), with or without history of bleeding associated with diagnosis of MDS, OR - ≤ 50 x 10\^9/L, (with no individual count >60 x 10\^9/L during the screening period) with a history of bleeding associated with the diagnosis of MDS. • Patients must be ≥18 and ≤ 90 years of age at time of . Patients between 85 and 90 years of age must have been diagnosed with MDS ≤ 5 years from study start. • (ECOG) performance status of 0-2. • Adequate liver function, as evidenced by (ALT) ≤ 3 times laboratory normal range, aspartate aminotransferase (AST) ≤ 3 times laboratory normal range and total ≤ 2.0 times laboratory normal range. (Adequate liver function for patients with confirmed diagnosis of Gilbert's Disease evidenced by ALT ≤ 3 times laboratory normal range, and AST ≤ 3 times laboratory normal range.) • Serum creatinine concentration ≤ 2 mg/dl (≤176.8 μmol/L). • Bone marrow and aspirate with cytogenetics within 3 months of starting first dose of product. • Written Informed Consent. Exclusion Criteria: • Have ever received any disease-modifying treatment for MDS. • Previously diagnosed with intermediate-2 or high risk MDS using the IPSS. • Prior history of leukemia, aplastic anemia, or other non-MDS related bone marrow stem cell disorder. • Prior history of hematopoietic stem cell transplantation. • Persistent peripheral blood monocytosis (≥ 3 months with an absolute monocyte count >1,000/μL) or known diagnosis of Chronic Myelomonocytic Leukemia per French-American-British Classification System for MDS (FAB) criteria. • Prior (other than in situ cervical cancer, non-melanoma skin cancer, or in situ carcinoma) unless treated with curative intent and without evidence of disease for ≥ 3 years before randomization. • Active or uncontrolled infections. • Unstable angina, congestive heart failure ( [NYHA] > class II), uncontrolled hypertension (diastolic >100 mmHg), uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction. • History of arterial thrombosis (eg, stroke or ) within the past year. • History of venous thrombosis that currently requires anti-coagulation therapy. • Received Interleukin (IL)-11 within 4 weeks of first dose of investigational product. • Have previously received any thrombopoietic growth factor. • Receipt of granulocyte-colony stimulating factor, (G-CSF), pegylated-G-CSF, or granulocyte macrophage-colony stimulating factor (GM-CSF) within 4 weeks of first dose of investigational product. • Planned receipt of peg-G-CSF or GM-CSF after first dose of investigational product. • Pregnant or breast feeding. • Patients of who are not using adequate precautions, in the judgment of the investigator. Amgen recommends double barrier contraception is used for all applicable patients enrolled on this study. A double barrier method is defined as two methods of contraception, for example 2 actual barrier methods, or one actual barrier method and one hormonal method. • Patient has known sensitivity to any recombinant E coli-derived product (eg, Infergen®, Neupogen®, Somatropin, and Actimmune). • Previously enrolled into the 20060198 study or another romiplostim study. • Inability to comply with study procedures. • Patient currently is enrolled in or has not yet completed at least 30 days since ending other investigational device or drug study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weekly subcutaneous dosing based on platelet count for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period. Starting dose is at 750 μg, up to a maximum dose of 1000 μg, or reduced to a minimum of 250 μg.
Biological: Romiplostim
Weekly subcutaneous dosing with blinded matching placebo dose level for 26 weeks during the Test Treatment Period and for 24 weeks during the Extended Treatment Period, separated by a 4-week interim washout period.
Drug: Placebo
Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
Number of Clinically Significant Bleeding Events
A clinically significant bleeding event is defined as any bleeding event of grade ≥ 2 per the modified World Health Organization (WHO) bleeding scale: • Grade 0 = no bleeding • Grade 1 = petechia or mucosal or retinal bleeding not requiring intervention • Grade 2 = melena, hematemesis, hematuria, hemoptysis • Grade 3 = bleeding required red cell transfusion • Grade 4 = retinal bleeding with visual impairment • Grade 5 = non-fatal cerebral bleeding • Grade 6 = fatal cerebral bleeding • Grade 7 = fatal non-cerebral bleeding. Bleeding events that continue for more than 7 days were counted as separate events every eighth day. Multiple events that arose from one organ system on one day were collapsed into one single event. Bleeding events with a start date between the first dose date and the last dose date of the test treatment period+7 days are included.
Time frame: Test Treatment Period (Weeks 1-26)
Annualized Rate of Platelet Transfusion Events
A discrete platelet transfusion is any number of platelet transfusion administered within a 3-day period. Transfusions administered more than 3 days apart are counted as separate events. Transfusion given in the absence of any bleeding, when platelet count is \>10x10\^9/L, is not counted as a platelet transfusion event. Events with start date between the first dose date and the last dose date of the test treatment period +7 days are included. Exposure adjusted event rate per 100 patient-years = (events / patient-years \* 100). Patient Year = total patient years of exposure to investigational product during 26 weeks test treatment period.
Time frame: Test Treatment Period (Weeks 1-26)
Annualized Rate of Overall Bleeding Events
The time from first dose of study drug to the last dose of 26-week test treatment period. A bleeding event is defined as any bleeding event reported during the test treatment period. Bleeding events that continue for more than 7 days are counted as separate events every eighth day. Multiple events that arose from one organ system on one day are collapsed into one single event. Exposure adjusted event rate per 100 patient-years = events / patient-year \* 100).
Time frame: Test Treatment Period (Weeks 1-26)
Annualized Rate of Total Platelet Transfusion Units
The time from first dose of study drug to the last dose of 26-week test treatment period. A unit of platelets is defined as a single pack of pooled platelet-rich plasma comprised of 6 to 8 individual platelet concentrate packs (200 to 400 mL), a single pack of pooled buffy-coat concentrate, or 1 apheresis (single donor) concentrate. Exposure adjusted event rate per 100 patient-years = events / patient-years \* 100.
Time frame: Test Treatment Period (Weeks 1-26)
Number of Participants With Platelet Hematologic Improvement (HI-P)
Platelet Hematologic Improvemen defined by the international working group (IWG) as: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a patient starting with a platelet count of ≥ 20 x 10\^9/L or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a patient that started with a platelet count \< 20 x 10\^9/L. To account for any possible contribution from platelet transfusions, platelet counts within 3 days following administration of platelet transfusion is not counted towards the platelet hematologic improvement endpoint. If no platelet measurements are available on the weekly scheduled dose day, then that week is not counted towards the platelet hematologic improvement endpoint.
Time frame: Test Treatment Period (Weeks 1-26)
Exposure-adjusted Total Duration of Platelet Hematologic Improvement (HI-P) in the Absence of Platelet Transfusions
Duration for participants who did not report HI-P during the period is 0. A platelet hematologic improvement (HI-P) is defined by an MDS International Working criteria as patients with a baseline platelet count of ≥ 20 x 10\^9/L achieving an absolute increase of ≥ 30 x 10\^9/L or increasing the platelet count to above 20 x 10\^9/L and by at least 100% in patients with a baseline of \< 20 x 10\^9/L for at least 8 consecutive weeks. To account for any possible contribution from platelet transfusions, platelet counts within 3 days following administration of platelet transfusion is not counted towards the platelet hematologic improvement endpoint. If no platelet measurements are available on the weekly scheduled dose day, then that week is not counted towards the platelet hematologic improvement endpoint. The durations of HI-P are cumulative if more than one incidence occurred. Exposure adjusted event rate per 100 patient-weeks = total number of weeks / patient-weeks \* 100.
Time frame: Test Treatment Period (Weeks 1-26)
Number of Participants Who Died
Time frame: From randomization to 58 weeks, the end of study visit or the closest available follow-up information up to 58 weeks from the long term follow-up for those who discontinued the study early, with a data cut-off date of 20 July 2012.
Time to Death
Overall survival was calculated using Kaplan-Meier methods. For patients who discontinued early, additional information from the long term follow-up are added (closest available follow-up information up to 58 weeks).
Time frame: From randomization to 58 weeks, the end of study visit or the closest available follow-up information up to 58 weeks from the long term follow-up for those who discontinued the study early, with a data cut-off date of 20 July 2012.
Kaplan-Meier Estimate of Survival at Month 12
Overall survival was calculated using Kaplan-Meier methods.
Time frame: Month 12, with a data cut-off date of 20 July 2012.
Annualized Rate of Patient-reported Bleeding Events
The number of bleeding events was obtained from the thrombocytopenia symptoms (Th-symptoms) survey. Patients reported spontaneous bleeding to have occurred 0, 1 or 2, 3 or 4, 5 or 6, or 7 or more times in the past week. The lower threshold of bleeding counts is used for conservative purposes (i.e., the "3" is used for the response option of "3 or 4 times"). Exposure adjusted event rate per 100 patient-years = number of events / patient-year \* 100.
Time frame: Test Treatment Period (Weeks 1-26)
First Subject Enrolled: 21 July 2008, Last Subject Enrolled: 16 December 2010.
| Milestone | Placebo | Romiplostim |
|---|---|---|
| Started | 83 | 167 |
| Completed | 20 | 36 |
| Not completed | 63 | 131 |
| Withdrew: Adverse event | 4 | 20 |
| Withdrew: Death | 5 | 8 |
| Withdrew: Lack of efficacy | 9 | 11 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Protocol violation | 3 | 2 |
| Withdrew: Withdrawal by subject | 12 | 22 |
| Withdrew: Other | 6 | 11 |
| Withdrew: Ineligibility determined | 1 | 2 |
| Withdrew: Disease progression | 0 | 8 |
| Withdrew: Administrative decision | 23 | 46 |
A clinically significant bleeding event is defined as any bleeding event of grade ≥ 2 per the modified World Health Organization (WHO) bleeding scale: • Grade 0 = no bleeding • Grade 1 = petechia or mucosal or retinal bleeding not requiring intervention • Grade 2 = melena, hematemesis, hematuria, hemoptysis • Grade 3 = bleeding required red cell transfusion • Grade 4 = retinal bleeding with visual impairment • Grade 5 = non-fatal cerebral bleeding • Grade 6 = fatal cerebral bleeding • Grade 7 = fatal non-cerebral bleeding. Bleeding events that continue for more than 7 days were counted as separate events every eighth day. Multiple events that arose from one organ system on one day were collapsed into one single event. Bleeding events with a start date between the first dose date and the last dose date of the test treatment period+7 days are included.
| events | Placebo | Romiplostim |
|---|---|---|
| Number of Clinically Significant Bleeding Events | 116 | 178 |
A discrete platelet transfusion is any number of platelet transfusion administered within a 3-day period. Transfusions administered more than 3 days apart are counted as separate events. Transfusion given in the absence of any bleeding, when platelet count is \>10x10\^9/L, is not counted as a platelet transfusion event. Events with start date between the first dose date and the last dose date of the test treatment period +7 days are included. Exposure adjusted event rate per 100 patient-years = (events / patient-years \* 100). Patient Year = total patient years of exposure to investigational product during 26 weeks test treatment period.
| events per 100 patient-years | Placebo | Romiplostim |
|---|---|---|
| Annualized Rate of Platelet Transfusion Events | 1013.5 (905.2 to 1131.3) | 748.9 (681.3 to 821.4) |
The time from first dose of study drug to the last dose of 26-week test treatment period. A bleeding event is defined as any bleeding event reported during the test treatment period. Bleeding events that continue for more than 7 days are counted as separate events every eighth day. Multiple events that arose from one organ system on one day are collapsed into one single event. Exposure adjusted event rate per 100 patient-years = events / patient-year \* 100).
| events per 100 patient-years | Placebo | Romiplostim |
|---|---|---|
| Annualized Rate of Overall Bleeding Events | 3786.4 (3574.1 to 4008.0) | 3459.9 (3312.8 to 3611.9) |
The time from first dose of study drug to the last dose of 26-week test treatment period. A unit of platelets is defined as a single pack of pooled platelet-rich plasma comprised of 6 to 8 individual platelet concentrate packs (200 to 400 mL), a single pack of pooled buffy-coat concentrate, or 1 apheresis (single donor) concentrate. Exposure adjusted event rate per 100 patient-years = events / patient-years \* 100.
| units per 100 patient-years | Placebo | Romiplostim |
|---|---|---|
| Annualized Rate of Total Platelet Transfusion Units | 3120.2 (2927.8 to 3322.0) | 2221.8 (2104.2 to 2344.2) |
Platelet Hematologic Improvemen defined by the international working group (IWG) as: an absolute increase in platelet count of ≥ 30 x 10\^9/L for a patient starting with a platelet count of ≥ 20 x 10\^9/L or an increase in platelet count from \< 20 x 10\^9/L to ≥ 20 x 10\^9/L and by at least 100% in a patient that started with a platelet count \< 20 x 10\^9/L. To account for any possible contribution from platelet transfusions, platelet counts within 3 days following administration of platelet transfusion is not counted towards the platelet hematologic improvement endpoint. If no platelet measurements are available on the weekly scheduled dose day, then that week is not counted towards the platelet hematologic improvement endpoint.
| Participants | Placebo | Romiplostim |
|---|---|---|
| Number of Participants With Platelet Hematologic Improvement (HI-P) | 3 | 61 |
Duration for participants who did not report HI-P during the period is 0. A platelet hematologic improvement (HI-P) is defined by an MDS International Working criteria as patients with a baseline platelet count of ≥ 20 x 10\^9/L achieving an absolute increase of ≥ 30 x 10\^9/L or increasing the platelet count to above 20 x 10\^9/L and by at least 100% in patients with a baseline of \< 20 x 10\^9/L for at least 8 consecutive weeks. To account for any possible contribution from platelet transfusions, platelet counts within 3 days following administration of platelet transfusion is not counted towards the platelet hematologic improvement endpoint. If no platelet measurements are available on the weekly scheduled dose day, then that week is not counted towards the platelet hematologic improvement endpoint. The durations of HI-P are cumulative if more than one incidence occurred. Exposure adjusted event rate per 100 patient-weeks = total number of weeks / patient-weeks \* 100.
| weeks per 100 patient-weeks | Placebo | Romiplostim |
|---|---|---|
| Exposure-adjusted Total Duration of Platelet Hematologic Improvement (HI-P) in the Absence of Platelet Transfusions | 2.57 (1.85 to 3.47) | 35.02 (32.98 to 37.16) |
| participants | Placebo | Romiplostim |
|---|---|---|
| Number of Participants Who Died | 17 (NA to NA) | 30 (NA to NA) |
Overall survival was calculated using Kaplan-Meier methods. For patients who discontinued early, additional information from the long term follow-up are added (closest available follow-up information up to 58 weeks).
| months | Placebo | Romiplostim |
|---|---|---|
| Time to Death | NA (NA to NA) | NA (NA to NA) |
Overall survival was calculated using Kaplan-Meier methods.
| percentage of participants | Placebo | Romiplostim |
|---|---|---|
| Kaplan-Meier Estimate of Survival at Month 12 | 78 (67 to 86) | 83 (76 to 88) |
The number of bleeding events was obtained from the thrombocytopenia symptoms (Th-symptoms) survey. Patients reported spontaneous bleeding to have occurred 0, 1 or 2, 3 or 4, 5 or 6, or 7 or more times in the past week. The lower threshold of bleeding counts is used for conservative purposes (i.e., the "3" is used for the response option of "3 or 4 times"). Exposure adjusted event rate per 100 patient-years = number of events / patient-year \* 100.
| events per 100 patient-years | Placebo | Romiplostim |
|---|---|---|
| Annualized Rate of Patient-reported Bleeding Events | 1995 (1840.5 to 2158.9) | 1264 (1175.1 to 1357.7) |
Collected over 58 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 22/82 (26.8%) | 74/82 (90.2%) |
| Romiplostim | — | 67/168 (39.9%) | 146/168 (86.9%) |
| Event | Placebo | Romiplostim |
|---|---|---|
| PneumoniaInfections and infestations | 0/82 | 8/168 |
| AnaemiaBlood and lymphatic system disorders | 2/82 | 7/168 |
| PyrexiaGeneral disorders | 1/82 | 7/168 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/82 | 6/168 |
| Atrial fibrillationCardiac disorders | 1/82 | 5/168 |
| Febrile neutropeniaBlood and lymphatic system disorders | 2/82 | 2/168 |
| DiarrhoeaGastrointestinal disorders | 2/82 | 1/168 |
| Cerebral haemorrhageNervous system disorders | 2/82 | 0/168 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/82 | 1/168 |
| Head injuryInjury, poisoning and procedural complications | 0/82 | 4/168 |
| Event | Placebo | Romiplostim |
|---|---|---|
| HaematomaVascular disorders | 33/82 | 58/168 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 32/82 | 66/168 |
| PetechiaeSkin and subcutaneous tissue disorders | 20/82 | 42/168 |
| ContusionInjury, poisoning and procedural complications | 10/82 | 41/168 |
| Gingival bleedingGastrointestinal disorders | 14/82 | 33/168 |
| HaemorrhageVascular disorders | 15/82 | 24/168 |
| HeadacheNervous system disorders | 10/82 | 29/168 |
| NauseaGastrointestinal disorders | 7/82 | 27/168 |
| Oedema peripheralGeneral disorders | 7/82 | 26/168 |
| CoughRespiratory, thoracic and mediastinal disorders | 10/82 | 25/168 |
| Age, Continuous(years) | Placebo | Romiplostim | Total |
|---|---|---|---|
| Mean | 67 ± 11.5 | 68.4 ± 12 | 67.9 ± 11.8 |
| Sex: Female, Male(Participants) | Placebo | Romiplostim | Total |
|---|---|---|---|
| Female | 30 | 72 | 102 |
| Male | 53 | 95 | 148 |
| Race/Ethnicity, Customized(Participants) | Placebo | Romiplostim | Total |
|---|---|---|---|
| White or Caucasian | 79 | 156 | 235 |
| Black or African American | 0 | 1 | 1 |
| Hispanic or Latino | 1 | 4 | 5 |
| Asian | 1 | 1 | 2 |
| Other | 2 | 5 | 7 |
| Myelodysplastic Syndromes World Health Organization Classification(Participants) | Placebo | Romiplostim | Total |
|---|---|---|---|
| RA | 5 | 6 | 11 |
| RARS | 0 | 2 | 2 |
| RAEB-1 | 9 | 24 | 33 |
| RAEB-2 | 0 | 1 | 1 |
| RCMD | 55 | 114 | 169 |
| RCMD-RS | 2 | 4 | 6 |
| MDS-U | 12 | 16 | 28 |
| MDS associated with isolated del 5Q | 0 | 0 | 0 |
| Prior MDS Therapy(Participants) | Placebo | Romiplostim | Total |
|---|---|---|---|
| No | 70 | 133 | 203 |
| Yes | 13 | 34 | 47 |
| Baseline Platelet Counts(10^9/L) | Placebo | Romiplostim | Total |
|---|---|---|---|
| Mean | 21.5 ± 13 | 22.3 ± 11.5 | 22.0 ± 12.0 |
| International Prognostic Scoring System (IPSS) Total Score(Participants) | Placebo | Romiplostim | Total |
|---|---|---|---|
| 0 | 23 | 40 | 63 |
| 0.5 | 38 | 86 | 124 |
| 1 | 20 | 34 | 54 |
| 1.5 | 0 | 1 | 1 |
| Missing | 2 | 6 | 8 |
No study locations are listed for this record.
Ran from Jul 2008 to primary completion in Mar 2011, 32 months.
Results were first posted in Aug 2013, 2 years 4 months after primary completion.
Of 52 industry-sponsored phase 2 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 32 months is below that.
Counting every sponsor, half of 279 studies reached it within 66 months; a quarter within 40 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Romiplostim